Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study

Table 3 Prognostic value of Bcl-2 expression estimated by multivariate analysis in the global cohort of 180 FMCs

	Categories	p	HR	95%-CI
Disease-free interval
Bcl-2 expression	Bcl-2+ versus Bcl-2–	0.034	0.57	0.34–0.96
Pathologic tumor size	pT ≥ 20 mm versus < 20 mm	0.029	1.52	1.04–2.21
Pathologic nodal stage	pNX versus pN0	0.109	1.71	0.89–3.28
Pathologic nodal stage	pN+ versus pN0	0.007	2.36	1.27–4.41
Overall survival
Bcl-2 expression	Bcl-2+ versus Bcl-2–	0.015	0.58	0.37–0.90
Pathologic tumor size	pT ≥ 20 mm versus < 20 mm	0.002	1.64	1.20–2.25
Pathologic nodal stage	pNX versus pN0	0.252	1.38	0.80–2.36
Pathologic nodal stage	pN+ versus pN0	0.003	2.15	1.30–3.55
Distant metastasis	MX versus M0	0.083	0.74	0.53–1.04
Distant metastasis	M1 versus M0	0.034	2.28	1.07–4.87
Tumor-associated inflammation	Absence to mild versus moderate to severe	0.034	0.71	0.51–0.97
Cancer-specific survival
Bcl-2 expression	Bcl-2+ versus Bcl-2–	0.008	0.50	0.30–0.84
Pathologic tumor size	pT ≥ 20 mm versus < 20 mm	0.002	1.78	1.24–2.55
Pathologic nodal stage	pNX versus pN0	0.296	1.42	0.74–2.75
Pathologic nodal stage	pN+ versus pN0	0.002	2.63	1.44–4.80
Distant metastasis	MX versus M0	0.026	0.65	0.44–0.95
Distant metastasis	M1 versus M0	0.022	2.47	1.14–5.32

ISSN: 1746-6148